$IRMD News

IRADIMED (NASDAQ:IRMD) Beats Q2 EPS, Reaffirms Full-Year Guidance

IRADIMED CORPORATION (IRMD) Q2 2026 Earnings Call Transcript

iRadimed Sees Q3 Adj EPS $0.54-$0.59 vs $0.52 Est; Sees Sales $23.000M-$24.500M vs $23.650M Est

iRadimed Affirms FY2026 GAAP EPS Guidance of $1.90-$2.05 vs $1.91 Est

CORRECTION: iRadimed Raises FY2026 Adj EPS Guidance from $2.06-$2.21 to $2.09-$2.24 vs $2.08 Est; Affirms FY2026 Sales Guidance of $91.000M-$96.000M vs $91.300M Est

iRadimed Sees Q3 GAAP EPS $0.49-$0.54 vs $0.49 Est

Assessing IRADIMED (IRMD) Valuation After Strong Multi Year Returns And A Premium P/E Multiple

IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed’s CEO and Founder Sold 7,500 Company Shares. What Does That Mean for Investors?

IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Reaffirmed Outlook And Dividend: What Does IRMD’s Confidence Signal About Its MRI Pump Moat?

Here's What We Like About IRADIMED's (NASDAQ:IRMD) Upcoming Dividend

A Look At IRADIMED (IRMD) Valuation As Long Term Returns Contrast With Recent Share Price Weakness

IRadimed Corporation Q1 2026 Earnings Call Summary

iRadimed Corp (IRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and New Product Demand

IRADIMED CORPORATION (IRMD) Q1 2026 Earnings Call Transcript

iRadimed Q1 Earnings Call Highlights

IRADIMED (NASDAQ:IRMD) Beats Q1 Estimates, But Cautious Q2 Guidance Tempers Outlook

IRADIMED CORPORATION Reports First Quarter 2026 Financial Results